Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)

NCT05445934 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

1188

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: FB2001
DRUG: FB2001 placebo

Sponsor

Frontier Biotechnologies Inc.